Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929959 | 0.84 | RAB9A (0.46) | LMNAALDH1A1HTTSMN1; SMN2MAPK1 | |
| SCHEMBL30883901 | 0.84 | RAB9A (0.46) | LMNAALDH1A1HTTSMN1; SMN2MAPK1 | |
| SCHEMBL1021384 | 0.81 | CA2 (0.48) | ALDH1A1MAPK1 | |
| SCHEMBL3151542 | 0.79 | HTT (0.45) | LMNAALDH1A1HTTGAAHPGD | |
| SCHEMBL28996996 | 0.78 | ACHE (0.35) | GRM4ALDH1A1 | |
| SCHEMBL3151764 | 0.77 | EPHX2 (0.36) | — | |
| SCHEMBL1021627 | 0.76 | L3MBTL1 (0.41) | GRM4ALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL9318464 | 0.74 | L3MBTL1 (0.38) | LMNA | |
| SCHEMBL1021779 | 0.73 | ALOX15 (0.42) | LMNAALDH1A1HPGDSMN1; SMN2MAPK1 | |
| SCHEMBL667921 | 0.73 | CES2 (0.36) | NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262057-B1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3262057-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135582-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20100004289-A1 | SUBSTITUTED BUTYROPHENONE DERIVATIVES | CLERA INC. (CA) | 2010-01-07 | — | — | US | disclosed |
| EP-1874730-A4 | SUBSTITUTED BUTYROPHENONE DERIVATIVES | CLERA INC (CA) | 2009-06-10 | — | — | EP | disclosed |
| EP-1874730-A1 | SUBSTITUTED BUTYROPHENONE DERIVATIVES | Clera Inc. (CA) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006116848-A1 | SUBSTITUTED BUTYROPHENONE DERIVATIVES | CLERA INC. (CA) | 2006-11-09 | — | — | WO | disclosed |
| US-6599920-B2 | Antiestrogenic compound having fewer or no estrogen agonist properties on reproductive tissues | ELI LILLY AND COMPANY | 2003-07-29 | — | — | US | disclosed |
| EP-0826670-B1 | Naphthalene compounds, intermediates, formulations, and methods | LILLY CO ELI (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-0826680-B1 | Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods of preparation thereof. | LILLY CO ELI (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6020513-A | BONE DISORDERS | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| US-5958916-A | FOR INHIBITING BONE LOSS OR BONE RESORPTION | ELI LILLY AND COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0826680-A1 | Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
| EP-0826670-A1 | Naphthalene compounds, intermediates, formulations, and methods | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
| EP-0175452-B1 | 1,3-DISUBSTITUTED PIPERIDINE COMPOUNDS AS NEUROLEPTIC AGENTS | PFIZER INC. (US) | 1988-09-21 | — | — | EP | disclosed |
| US-4623728-A | NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1986-11-18 | — | — | US | disclosed |
| US-4593037-A | Compound substituted with phenyl rings | PFIZER INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0175452-A1 | 1,3-Disubstituted piperidine compounds as neuroleptic agents | PFIZER INC. (US) | 1986-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | AMY1A 3989/4885LMNA 599/4885GRM4 4239/4885 |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | AMY1A 3413/4885LMNA 678/4885GRM4 4572/4885 |
| US-20100004289-A1 | SUBSTITUTED BUTYROPHENONE DERIVATIVES | DBH, SLC6A3, GABBR1 | AMY1A 3721/4885LMNA 4739/4885GRM4 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.